Evotec (NASDAQ:EVO) Shares Gap Up to $7.07

Shares of Evotec SE (NASDAQ:EVO) gapped up prior to trading on Monday . The stock had previously closed at $7.07, but opened at $7.36. Evotec shares last traded at $7.35, with a volume of 15,314 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EVO. Royal Bank of Canada raised Evotec from a “sector perform” rating to an “outperform” rating in a research note on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised Evotec from a “hold” rating to a “buy” rating in a research note on Friday, April 12th.

Evotec Trading Up 3.9 %

The business has a 50 day simple moving average of $7.37 and a two-hundred day simple moving average of $8.71.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Quadrant Capital Group LLC acquired a new stake in shares of Evotec during the 4th quarter worth $25,000. Optiver Holding B.V. increased its holdings in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC acquired a new stake in Evotec in the 4th quarter valued at $53,931,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.